Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Prevents acute and delayed nausea and vomiting associated with initial and repeat courses…. Sold as Aloxi, Posfrea, Palonosetron Hydrochloride. Every FDA application for this active ingredient: 5 branded and 19 generic.
As of Nov 16, 2026, FDA lists 24 applications for Palonosetron Hydrochloride (sold as Aloxi, Posfrea, Palonosetron Hydrochloride), first approved Jul 25, 2003, with 7 new uses approved and 0 published complete response letters.
First approved: Jul 25, 2003
Applications: 24
New uses approved: 7
Complete response letters: 0
Medicare spending, 2025: $25.2M
First approved in the EU: Mar 22, 2005
First approved in Japan: Jan 20, 2010
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
POSFREA
Part B
$23.7M
New
8,903
Aloxi
Part B
$1.1M
-55%
40,339
Palonosetron HCl
Part D
$308K
+24%
1,499
Posfrea
Part D
$58K
New
38
Approvals in the EU (EMA)
First approved in the EU 20 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
First approved in Japan 78 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
AloxiDrugs with a new additional pediatric dosage indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from… · Taiho Pharmaceutical Co., Ltd. · May 27, 2021
Aloxi, new ingredientA drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the… · Taiho Pharmaceutical Co., Ltd. · Jan 20, 2010
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA